대상포진 후 신경통 치료 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2031년) - 치료 유형별, 유통 채널별, 지역별

Post Herpetic Neuralgia Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region:

US $ 4,995 ￦ 6,947,000

Unprintable PDF & Excel (Single User License)

PDF 및 Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 텍스트의 Copy&Paste도 불가능합니다.

US $ 8,495 ￦ 11,814,000

Unprintable PDF & Excel (Multi User License upto 5 users)

PDF 및 Excel 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 텍스트는 Copy & Paste 가능하지만, 인쇄는 불가능합니다.

US $ 10,600 ￦ 14,742,000

Printable PDF & Excel (Enterprise License above 5 users)

PDF 및 Excel 보고서를 동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용자수는 5명 이상이며 제한은 없습니다. Copy & Paste 및 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

대상포진 후 신경통(PHN)은 수두 대상포진 바이러스(대상포진)의 재활성화로 인한 말초신경 손상으로 인한 중등도에서 중증의 신경통이 특징이며, 대상포진 후 신경통은 대상포진 재활성화 후 30일 이상 지속되는 신경통입니다. 대상포진 후 신경통 치료 세계 시장은 Pfizer Inc., Teva Pharmaceutical Industries Ltd. 50% 이상을 차지하고 있습니다. 이들 주요 업체들은 대상포진 후 신경통 치료에 대한 인식이 높아지고 노인 인구가 증가함에 따라 시장을 주도하고 있습니다.

대상포진 후 신경통 치료 시장에서 대형 업체들이 우위를 점하고 있지만, 특허 만료 및 치료 옵션과 관련된 유효성 및 효율성 문제로 인해 통합이 반드시 수익성 향상으로 이어지지는 않습니다. 그러나 대상포진 후 신경통 치료에 대한 인식이 높아지면서, 특히 고령층에서 대상포진 후 신경통 치료에 대한 인식이 높아짐에 따라 시장 역학이 변화하고 있습니다.

세계 대상포진 후 신경통 치료 시장은 대상포진 후 신경통의 유병률 증가와 노인 인구의 증가로 인해 성장세를 보이고 있습니다. 또한, 세계 헬스케어 인프라 개선과 대상포진 후 신경통 치료 제품에 대한 정부 지원이 시장 성장의 원동력이 될 것으로 예상됩니다.

대상포진 후 신경통 치료 시장의 중요한 촉진요인은 검진율 증가와 노인 인구의 증가입니다. 미국 질병통제예방센터(CDC)에 따르면, 미국 성인 대상포진 발병률은 증가하고 있으며, 약 3명 중 1명은 평생 대상포진에 걸릴 것으로 추정됩니다. 대상포진 환자의 상당수가 대상포진 후 신경통으로 이어지며, 특히 50세 이상의 노인들에게서 많이 발생합니다.

시장의 잠재력에도 불구하고, 오피오이드 사용에 대한 우려와 과다 복용으로 인한 사망률 증가는 대상포진 후 신경통 치료 시장에 큰 제약을 가하고 있습니다. 약물 과다 복용으로 인한 사망의 상당 부분을 차지하는 오피오이드 과다 복용으로 인한 사망은 치료 옵션에 대한 우려를 높이고 있습니다.

이 보고서는 세계 대상포진 후 신경통 치료 시장에 대해 조사했으며, 시장 개요와 함께 치료 유형별, 유통 채널별, 지역별 동향, 시장 진입 기업의 경쟁 동향 등을 조사하여 전해드립니다.

목차

제1장 주요 요약

제2장 시장 개요

• 시장 정의와 세분화
• 시장 역학
• 밸류체인 분석
• Porter's Five Forces 분석
• COVID-19의 영향 분석
• 우크라이나와 러시아 분쟁의 영향
• 경제 개요
• PESTLE 분석

제3장 세계의 대상포진 후 신경통 치료 시장 전망, 2018-2031년

• 세계의 대상포진 후 신경통 치료 시장 전망, 치료 유형별, 금액(10억 달러), 2018-2031년
• 세계의 대상포진 후 신경통 치료 시장 전망, 유통 채널별, 금액(10억 달러), 2018-2031년
• 세계의 대상포진 후 신경통 치료 시장 전망, 지역별, 금액(10억 달러), 2018-2031년

제4장 북미의 대상포진 후 신경통 치료 시장 전망, 2018-2031년

제5장 유럽의 대상포진 후 신경통 치료 시장 전망, 2018-2031년

제6장 아시아태평양의 대상포진 후 신경통 치료 시장 전망, 2018-2031년

제7장 라틴아메리카의 대상포진 후 신경통 치료 시장 전망, 2018-2031년

제8장 중동 및 아프리카의 대상포진 후 신경통 치료 시장 전망, 2018-2031년

제9장 경쟁 상황

• 치료 유형과 유통 채널 히트맵
• 제조업체와 유통 채널 히트맵
• 기업의 시장 점유율 분석, 2023년
• 경쟁 대시보드
• 기업 개요
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Mylan N.V.
  • Endo Pharmaceuticals Inc.
  • Daiichi Sankyo
  • Acorda Therapeutics
  • Purdue Pharma L.P
  • Teikoku Pharma USA, Inc.
  • Janssen Pharmaceuticals, Inc.

제10장 부록

ksm

영문 목차

영문목차

Post herpetic neuralgia (PHN) is characterized by moderate to severe nerve pain resulting from damage to a peripheral nerve due to the reactivation of the varicella zoster virus (shingles). PHN is nerve pain that persists for more than 30 days after the reactivation of herpes zoster.The global post herpetic neuralgia treatment market is predominantly driven by key players, including Pfizer Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., and Endo Pharmaceuticals Inc., who collectively account for more than 50% of the market's revenue. These leading manufacturers are capitalizing on growing awareness about post herpetic neuralgia treatment and the increasing geriatric population.

Market Consolidation and Challenges

While large vendors dominate the post herpetic neuralgia treatment market, consolidation hasn't necessarily translated into increased profitability due to patent expirations and the effectiveness and efficiency challenges associated with treatment options. However, the market's dynamics are evolving as awareness about post herpetic neuralgia treatment grows, especially among the elderly.

Drivers of Market Growth

The global post herpetic neuralgia treatment market is experiencing growth due to the rising prevalence of post herpetic neuralgia and the expanding geriatric population. Furthermore, the development of healthcare infrastructure globally, coupled with government support for post herpetic neuralgia treatment products, is expected to drive market growth.

Growing Geriatric Population and Screening Rates

The increasing rates of screening and the growth in the geriatric population are critical drivers of the post herpetic neuralgia treatment market. According to the Center for Disease Control and Prevention, shingles is on the rise among adults in the United States, with approximately 1 in 3 people developing shingles in their lifetime. A significant percentage of shingles cases result in post herpetic neuralgia, particularly in individuals aged 50 and older.

Concerns Over Opioid Use

Despite the market's potential, concerns over opioid use and the rising mortality rates due to overdoses pose significant constraints on the post herpetic neuralgia treatment market. Opioid overdose deaths, accounting for a substantial portion of drug overdose fatalities, have raised concerns over treatment options.

Opportunities in New Drug Development

The development of new drugs presents a significant opportunity in the post herpetic neuralgia treatment market, as a definitive curative treatment is yet to be discovered. Government support for post herpetic neuralgia treatment products, particularly through initiatives and investments in research and development, is expected to foster market growth.

Regional Variations in Market Growth

In developed regions like North America and Europe, the presence of a larger economy, higher purchasing power, and extensive healthcare infrastructure support the growth of the post herpetic neuralgia treatment market. The U.S., in particular, stands out due to excellent reimbursement policies and increasing incidence rates of post herpetic neuralgia. In Asia Pacific, Japan, India, Australia, and New Zealand are key players in the market.

Challenges to Market Realization

Despite the market's potential, challenges remain, particularly related to the efficacy and efficiency of treatment options. While calcium-channel blockers, tricyclic antidepressants, steroids, and opioids are used in post herpetic neuralgia treatment, they have limitations and side effects that restrict their widespread use.

Competitive Analysis

The post herpetic neuralgia treatment market features key players such as Pfizer Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Endo Pharmaceuticals Inc., and others. These players are profiled in the competition section of the report, outlining their market shares, strategies, product offerings, marketing approaches, and company dashboards.

Post Herpetic Neuralgia Treatment Market Segmentation:

The report presents a detailed segmentation of the post-herpetic neuralgia treatment market based on treatment type, distribution channels, and region. The treatment types include drugs, patches, and steroid injectables. Within the drug segment, further subdivisions are made for anticonvulsants, antidepressants, and opioids.

Under the patches segment, there are subdivisions for lidocaine skin patches and capsaicin skin patches. Distribution channels comprise institutional sales, which encompass hospital pharmacies and clinics, and retail sales, which include retail pharmacies, drug stores, and mail-order pharmacies.

The post-herpetic neuralgia treatment market analysis covers regions including North America, Latin America, Europe, Asia Pacific excluding China, China, and the Middle East and Africa.

Table of Contents

1. Executive Summary

• 1.1. Global Post Herpetic Neuralgia Treatment Market Snapshot
• 1.2. Future Projections
• 1.3. Key Market Trends
• 1.4. Regional Snapshot, by Value, 2023
• 1.5. Analyst Recommendations

2. Market Overview

• 2.1. Market Definitions and Segmentations
• 2.2. Market Dynamics
  • 2.2.1. Drivers
  • 2.2.2. Restraints
  • 2.2.3. Market Opportunities
• 2.3. Value Chain Analysis
• 2.4. Porter's Five Forces Analysis
• 2.5. COVID-19 Impact Analysis
  • 2.5.1. Supply
  • 2.5.2. Demand
• 2.6. Impact of Ukraine-Russia Conflict
• 2.7. Economic Overview
  • 2.7.1. World Economic Projections
• 2.8. PESTLE Analysis

3. Global Post Herpetic Neuralgia Treatment Market Outlook, 2018 - 2031

• 3.1. Global Post Herpetic Neuralgia Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2018 - 2031
  • 3.1.1. Key Highlights
    • 3.1.1.1. Drugs
      • 3.1.1.1.1. Anticonvulsants
      • 3.1.1.1.2. Antidepressants
      • 3.1.1.1.3. Opioids
    • 3.1.1.2. Patches
      • 3.1.1.2.1. Lidocaine Patches
      • 3.1.1.2.2. Capsaicin Patches
    • 3.1.1.3. Steroid Injectable
• 3.2. Global Post Herpetic Neuralgia Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
  • 3.2.1. Key Highlights
    • 3.2.1.1. Institutional Sales
      • 3.2.1.1.1. Hospital Pharmacies
      • 3.2.1.1.2. Clinics
    • 3.2.1.2. Retail Sales
      • 3.2.1.2.1. Retail Pharmacies
      • 3.2.1.2.2. Drug Stores
      • 3.2.1.2.3. Mail Order Pharmacies
• 3.3. Global Post Herpetic Neuralgia Treatment Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
  • 3.3.1. Key Highlights
    • 3.3.1.1. North America
    • 3.3.1.2. Europe
    • 3.3.1.3. Asia Pacific
    • 3.3.1.4. Latin America
    • 3.3.1.5. Middle East & Africa

4. North America Post Herpetic Neuralgia Treatment Market Outlook, 2018 - 2031

• 4.1. North America Post Herpetic Neuralgia Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2018 - 2031
  • 4.1.1. Key Highlights
    • 4.1.1.1. Drugs
      • 4.1.1.1.1. Anticonvulsants
      • 4.1.1.1.2. Antidepressants
      • 4.1.1.1.3. Opioids
    • 4.1.1.2. Patches
      • 4.1.1.2.1. Lidocaine Patches
      • 4.1.1.2.2. Capsaicin Patches
    • 4.1.1.3. Steroid Injectable
• 4.2. North America Post Herpetic Neuralgia Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
  • 4.2.1. Key Highlights
    • 4.2.1.1. Institutional Sales
      • 4.2.1.1.1. Hospital Pharmacies
      • 4.2.1.1.2. Clinics
    • 4.2.1.2. Retail Sales
      • 4.2.1.2.1. Retail Pharmacies
      • 4.2.1.2.2. Drug Stores
      • 4.2.1.2.3. Mail Order Pharmacies
• 4.3. North America Post Herpetic Neuralgia Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
  • 4.3.1. Key Highlights
    • 4.3.1.1. U.S. Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
    • 4.3.1.2. U.S. Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 4.3.1.3. Canada Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
    • 4.3.1.4. Canada Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  • 4.3.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Post Herpetic Neuralgia Treatment Market Outlook, 2018 - 2031

• 5.1. Europe Post Herpetic Neuralgia Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2018 - 2031
  • 5.1.1. Key Highlights
    • 5.1.1.1. Drugs
      • 5.1.1.1.1. Anticonvulsants
      • 5.1.1.1.2. Antidepressants
      • 5.1.1.1.3. Opioids
    • 5.1.1.2. Patches
      • 5.1.1.2.1. Lidocaine Patches
      • 5.1.1.2.2. Capsaicin Patches
    • 5.1.1.3. Steroid Injectable
• 5.2. Europe Post Herpetic Neuralgia Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
  • 5.2.1. Key Highlights
    • 5.2.1.1. Institutional Sales
      • 5.2.1.1.1. Hospital Pharmacies
      • 5.2.1.1.2. Clinics
    • 5.2.1.2. Retail Sales
      • 5.2.1.2.1. Retail Pharmacies
      • 5.2.1.2.2. Drug Stores
      • 5.2.1.2.3. Mail Order Pharmacies
• 5.3. Europe Post Herpetic Neuralgia Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
  • 5.3.1. Key Highlights
    • 5.3.1.1. Germany Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
    • 5.3.1.2. Germany Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.3.1.3. U.K. Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
    • 5.3.1.4. U.K. Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.3.1.5. France Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
    • 5.3.1.6. France Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.3.1.7. Italy Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
    • 5.3.1.8. Italy Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.3.1.9. Turkey Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
    • 5.3.1.10. Turkey Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.3.1.11. Russia Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
    • 5.3.1.12. Russia Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.3.1.13. Rest of Europe Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
    • 5.3.1.14. Rest of Europe Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  • 5.3.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Post Herpetic Neuralgia Treatment Market Outlook, 2018 - 2031

• 6.1. Asia Pacific Post Herpetic Neuralgia Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2018 - 2031
  • 6.1.1. Key Highlights
    • 6.1.1.1. Drugs
      • 6.1.1.1.1. Anticonvulsants
      • 6.1.1.1.2. Antidepressants
      • 6.1.1.1.3. Opioids
    • 6.1.1.2. Patches
      • 6.1.1.2.1. Lidocaine Patches
      • 6.1.1.2.2. Capsaicin Patches
    • 6.1.1.3. Steroid Injectable
• 6.2. Asia Pacific Post Herpetic Neuralgia Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
  • 6.2.1. Key Highlights
    • 6.2.1.1. Institutional Sales
      • 6.2.1.1.1. Hospital Pharmacies
      • 6.2.1.1.2. Clinics
    • 6.2.1.2. Retail Sales
      • 6.2.1.2.1. Retail Pharmacies
      • 6.2.1.2.2. Drug Stores
      • 6.2.1.2.3. Mail Order Pharmacies
• 6.3. Asia Pacific Post Herpetic Neuralgia Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
  • 6.3.1. Key Highlights
    • 6.3.1.1. China Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
    • 6.3.1.2. China Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.3.1.3. Japan Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
    • 6.3.1.4. Japan Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.3.1.5. South Korea Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
    • 6.3.1.6. South Korea Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.3.1.7. India Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
    • 6.3.1.8. India Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.3.1.9. Southeast Asia Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
    • 6.3.1.10. Southeast Asia Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.3.1.11. Rest of Asia Pacific Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
    • 6.3.1.12. Rest of Asia Pacific Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  • 6.3.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Post Herpetic Neuralgia Treatment Market Outlook, 2018 - 2031

• 7.1. Latin America Post Herpetic Neuralgia Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2018 - 2031
  • 7.1.1. Key Highlights
    • 7.1.1.1. Drugs
      • 7.1.1.1.1. Anticonvulsants
      • 7.1.1.1.2. Antidepressants
      • 7.1.1.1.3. Opioids
    • 7.1.1.2. Patches
      • 7.1.1.2.1. Lidocaine Patches
      • 7.1.1.2.2. Capsaicin Patches
    • 7.1.1.3. Steroid Injectable
• 7.2. Latin America Post Herpetic Neuralgia Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
  • 7.2.1. Key Highlights
    • 7.2.1.1. Institutional Sales
      • 7.2.1.1.1. Hospital Pharmacies
      • 7.2.1.1.2. Clinics
    • 7.2.1.2. Retail Sales
      • 7.2.1.2.1. Retail Pharmacies
      • 7.2.1.2.2. Drug Stores
      • 7.2.1.2.3. Mail Order Pharmacies
• 7.3. Latin America Post Herpetic Neuralgia Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
  • 7.3.1. Key Highlights
    • 7.3.1.1. Brazil Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
    • 7.3.1.2. Brazil Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 7.3.1.3. Mexico Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
    • 7.3.1.4. Mexico Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 7.3.1.5. Argentina Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
    • 7.3.1.6. Argentina Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 7.3.1.7. Rest of Latin America Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
    • 7.3.1.8. Rest of Latin America Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  • 7.3.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Post Herpetic Neuralgia Treatment Market Outlook, 2018 - 2031

• 8.1. Middle East & Africa Post Herpetic Neuralgia Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2018 - 2031
  • 8.1.1. Key Highlights
    • 8.1.1.1. Drugs
      • 8.1.1.1.1. Anticonvulsants
      • 8.1.1.1.2. Antidepressants
      • 8.1.1.1.3. Opioids
    • 8.1.1.2. Patches
      • 8.1.1.2.1. Lidocaine Patches
      • 8.1.1.2.2. Capsaicin Patches
    • 8.1.1.3. Steroid Injectable
• 8.2. Middle East & Africa Post Herpetic Neuralgia Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
  • 8.2.1. Key Highlights
    • 8.2.1.1. Institutional Sales
      • 8.2.1.1.1. Hospital Pharmacies
      • 8.2.1.1.2. Clinics
    • 8.2.1.2. Retail Sales
      • 8.2.1.2.1. Retail Pharmacies
      • 8.2.1.2.2. Drug Stores
      • 8.2.1.2.3. Mail Order Pharmacies
• 8.3. Middle East & Africa Post Herpetic Neuralgia Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
  • 8.3.1. Key Highlights
    • 8.3.1.1. GCC Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
    • 8.3.1.2. GCC Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 8.3.1.3. South Africa Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
    • 8.3.1.4. South Africa Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 8.3.1.5. Egypt Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
    • 8.3.1.6. Egypt Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 8.3.1.7. Nigeria Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
    • 8.3.1.8. Nigeria Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 8.3.1.9. Nigeria Post Herpetic Neuralgia Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 8.3.1.10. Rest of Middle East & Africa Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
    • 8.3.1.11. Rest of Middle East & Africa Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  • 8.3.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

• 9.1. Treatment Type vs Distribution Channel Heatmap
• 9.2. Manufacturer vs Distribution Channel Heatmap
• 9.3. Company Market Share Analysis, 2023
• 9.4. Competitive Dashboard
• 9.5. Company Profiles
  • 9.5.1. Pfizer Inc.
    • 9.5.1.1. Company Overview
    • 9.5.1.2. Treatment Type Portfolio
    • 9.5.1.3. Financial Overview
    • 9.5.1.4. Business Strategies and Development
  • 9.5.2. Teva Pharmaceutical Industries Ltd.
    • 9.5.2.1. Company Overview
    • 9.5.2.2. Treatment Type Portfolio
    • 9.5.2.3. Financial Overview
    • 9.5.2.4. Business Strategies and Development
  • 9.5.3. Mylan N.V.
    • 9.5.3.1. Company Overview
    • 9.5.3.2. Treatment Type Portfolio
    • 9.5.3.3. Financial Overview
    • 9.5.3.4. Business Strategies and Development
  • 9.5.4. Endo Pharmaceuticals Inc.
    • 9.5.4.1. Company Overview
    • 9.5.4.2. Treatment Type Portfolio
    • 9.5.4.3. Financial Overview
    • 9.5.4.4. Business Strategies and Development
  • 9.5.5. Daiichi Sankyo
    • 9.5.5.1. Company Overview
    • 9.5.5.2. Treatment Type Portfolio
    • 9.5.5.3. Financial Overview
    • 9.5.5.4. Business Strategies and Development
  • 9.5.6. Acorda Therapeutics
    • 9.5.6.1. Company Overview
    • 9.5.6.2. Treatment Type Portfolio
    • 9.5.6.3. Financial Overview
    • 9.5.6.4. Business Strategies and Development
  • 9.5.7. Purdue Pharma L.P
    • 9.5.7.1. Company Overview
    • 9.5.7.2. Treatment Type Portfolio
    • 9.5.7.3. Financial Overview
    • 9.5.7.4. Business Strategies and Development
  • 9.5.8. Teikoku Pharma USA, Inc.
    • 9.5.8.1. Company Overview
    • 9.5.8.2. Treatment Type Portfolio
    • 9.5.8.3. Financial Overview
    • 9.5.8.4. Business Strategies and Development
  • 9.5.9. Janssen Pharmaceuticals, Inc.
    • 9.5.9.1. Company Overview
    • 9.5.9.2. Treatment Type Portfolio
    • 9.5.9.3. Financial Overview
    • 9.5.9.4. Business Strategies and Development

10. Appendix

• 10.1. Research Methodology
• 10.2. Report Assumptions
• 10.3. Acronyms and Abbreviations

관련자료